The risk of hepatocellular carcinoma HCC is decreasingafter the first 5 years of entecavir ETV or tenofovir TDF therapy in Caucasian chronic hepatitis B CHB patients

Papatheodoridis, G. V., YURTAYDIN S. C., Dalekos G. N., Buti M., Chi H., van Bömmel F., ...More

AASLD 2016, 11 November 2016, (Summary Text)

  • Publication Type: Conference Paper / Summary Text
  • Hacettepe University Affiliated: No